ENTITY

Medivation Inc (MDVN US)

21
Analysis
Health Care • United States
Medivation Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process.
more
•27 Oct 2016 13:36

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector:Mid-Week Update (October 27)

SummaryWe discuss our portfolio companies Acadia Pharmaceuticals Inc (ACAD US), Portola Pharmaceuticals Inc (PTLA US), Dynavax Technologies Corp...

•25 Oct 2016 10:24

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: October 24 (Monday)

Summary: We discuss Atyr Pharma Inc (LIFE US), DBV Technologies SA (DBV FP), Advaxis Inc (ADXS US), Global Blood Therapeutics Inc (GBT US),...

•20 Oct 2016 11:25

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: Mid-Week Update

Galapagos NV (GLPG NA) seems to have got some investor attention after the successful results of Celgene Corp (CELG US) anti-inflammatory product...

•19 Oct 2016 11:19

Recap of Key U.S. Biotechnology and Pharmaceutical Sector Events: October 17

Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate...

bullish•Astellas Pharma
•24 Aug 2016 06:24

Astellas: Pfizer Buying Medivation Is the Best Possible Outcome for the Japan Pharma Firm

Pfizer is to pay US$81.50/shr for Medivation, considerably above Sanofi’s original offer of US$52.5bil. This values the Xtandi-originator at...

x